POTENTIAL NEW DISEASE-MODIFYING TREATMENT IN LUNG TRANSPLANTATION
AI Therapeutics Inc., a clinical-stage biopharmaceutical company in Guilford, Connecticut, developing novel therapeutics for rare diseases, recently announced the commencement of an investigator initiated Phase 2 study at UC San Francisco (UCSF) for its novel inhaled form of sirolimus, LAM-001, for the treatment of bronchiolitis obliterans syndrome (BOS) in patients post-lung transplant. BOS remains the […]